Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L, Sullivan GM, Hexamer LA, Hasvold LA, Thalji R, Przytulinska M, Tao ZF, Li G, Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Merta P, Kovar P, Bouska JJ, Zhang H, Park C, Stewart KD, Sham HL, Sowin TJ, Rosenberg SH, Lin NH. Wang L, et al. Among authors: sullivan gm. J Med Chem. 2007 Aug 23;50(17):4162-76. doi: 10.1021/jm070105d. Epub 2007 Jul 21. J Med Chem. 2007. PMID: 17658776
Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives.
Gwaltney SL 2nd, O'Connor SJ, Nelson LT, Sullivan GM, Imade H, Wang W, Hasvold L, Li Q, Cohen J, Gu WZ, Tahir SK, Bauch J, Marsh K, Ng SC, Frost DJ, Zhang H, Muchmore S, Jakob CG, Stoll V, Hutchins C, Rosenberg SH, Sham HL. Gwaltney SL 2nd, et al. Among authors: sullivan gm. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62. doi: 10.1016/s0960-894x(03)00095-7. Bioorg Med Chem Lett. 2003. PMID: 12657282
Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.
Gwaltney SL 2nd, O'Connor SJ, Nelson LT, Sullivan GM, Imade H, Wang W, Hasvold L, Li Q, Cohen J, Gu WZ, Tahir SK, Bauch J, Marsh K, Ng SC, Frost DJ, Zhang H, Muchmore S, Jakob CG, Stoll V, Hutchins C, Rosenberg SH, Sham HL. Gwaltney SL 2nd, et al. Among authors: sullivan gm. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1363-6. doi: 10.1016/s0960-894x(03)00094-5. Bioorg Med Chem Lett. 2003. PMID: 12657283
Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.
Hasvold LA, Wang W, Gwaltney SL 2nd, Rockway TW, Nelson LT, Mantei RA, Fakhoury SA, Sullivan GM, Li Q, Lin NH, Wang L, Zhang H, Cohen J, Gu WZ, Marsh K, Bauch J, Rosenberg S, Sham HL. Hasvold LA, et al. Among authors: sullivan gm. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4001-5. doi: 10.1016/j.bmcl.2003.08.058. Bioorg Med Chem Lett. 2003. PMID: 14592494
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
Gu WZ, Joseph I, Wang YC, Frost D, Sullivan GM, Wang L, Lin NH, Cohen J, Stoll VS, Jakob CG, Muchmore SW, Harlan JE, Holzman T, Walten KA, Ladror US, Anderson MG, Kroeger P, Rodriguez LE, Jarvis KP, Ferguson D, Marsh K, Ng S, Rosenberg SH, Sham HL, Zhang H. Gu WZ, et al. Among authors: sullivan gm. Anticancer Drugs. 2005 Nov;16(10):1059-69. doi: 10.1097/00001813-200511000-00004. Anticancer Drugs. 2005. PMID: 16222147
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB. Ferguson D, et al. Among authors: sullivan gm. Clin Cancer Res. 2005 Apr 15;11(8):3045-54. doi: 10.1158/1078-0432.CCR-04-2041. Clin Cancer Res. 2005. PMID: 15837760
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. Souers AJ, et al. Among authors: sullivan gm. Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6. Nat Med. 2013. PMID: 23291630
Relationships between serotonin 1A receptor DNA methylation, self-reported history of childhood abuse and gray matter volume in major depression.
Goldenthal AR, Lieberman E, Rizk MM, Ogden RT, Rubin-Falcone H, Zanderigo F, Huang YY, Min E, Yuan M, Milak M, Sullivan GM, Sublette ME, Oquendo MA, Mann JJ, Miller JM. Goldenthal AR, et al. Among authors: sullivan gm. J Affect Disord. 2024 Dec 15;367:307-317. doi: 10.1016/j.jad.2024.08.148. Epub 2024 Aug 25. J Affect Disord. 2024. PMID: 39187183
Common Pitfalls to Avoid in Qualitative Submissions to JGME.
Gottlieb-Smith R, Balmer D, Yarris LM, Sullivan GM. Gottlieb-Smith R, et al. Among authors: sullivan gm. J Grad Med Educ. 2024 Aug;16(4):383-386. doi: 10.4300/JGME-D-24-00573.1. Epub 2024 Aug 15. J Grad Med Educ. 2024. PMID: 39148876 Free PMC article. No abstract available.
White matter damage and degeneration in traumatic brain injury.
Armstrong RC, Sullivan GM, Perl DP, Rosarda JD, Radomski KL. Armstrong RC, et al. Among authors: sullivan gm. Trends Neurosci. 2024 Sep;47(9):677-692. doi: 10.1016/j.tins.2024.07.003. Epub 2024 Aug 10. Trends Neurosci. 2024. PMID: 39127568 Free article. Review.
161 results